CC
CYTK icon

Checkpoint Capital’s Cytokinetics CYTK Stock Holding History

Checkpoint Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
180,000
+13,177
+8% +$837K 4.26% 5
2025
Q4 		$10.6M Buy
166,823
+129,236
+344% +$8.04M 3.31% 6
2025
Q3 		$2.07M Buy
+37,587
New +$1.55M 0.69% 10
2025
Q1 		– Sell
-20,000
Closed -$941K – 17
2024
Q4 		$941K Sell
20,000
-446,813
-96% -$23.2M 0.48% 16
2024
Q3 		$24.6M Buy
466,813
+276,813
+146% +$15.4M 12.23% 4
2024
Q2 		$10.3M Hold
190,000
– – 6.21% 6
2024
Q1 		$13.3M Sell
190,000
-40,000
-17% -$3.09M 8.9% 3
2023
Q4 		$19.2M Buy
+230,000
New +$8.33M 11.63% 3

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Checkpoint Capital's CYTK Position: Q1 2026 in Review

Checkpoint Capital increased its Cytokinetics (CYTK) stake by 7.9% in Q1 2026, buying an estimated $837K and bringing the position to 180,000 shares worth $11.9M. The position accounts for 4.26% of the portfolio, ranked #5.

Checkpoint Capital first reported a position in CYTK in Q4 2023 and has held it in 8 quarters since. The position peaked at $24.6M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Checkpoint Capital held 180,000 shares of Cytokinetics worth $11.9M as of Q1 2026.
  • Checkpoint Capital bought 13,177 Cytokinetics shares in Q1 2026, an estimated $837K.
  • Cytokinetics made up 4.26% of Checkpoint Capital's portfolio in Q1 2026, its #5 holding.
  • Checkpoint Capital first reported a position in Cytokinetics in Q4 2023 and has held it in 8 quarters since.
  • Checkpoint Capital's Cytokinetics position peaked at $24.6M in Q3 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Checkpoint Capital's 13F filing for Q1 2026, filed 15 May 2026.